11/18/2009 - Pfizer Inc. (NYSE:PFE) and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement to make advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease. The diseases afflict vulnerable populations in the developing world. Under the terms of the agreement, DNDi will have access to the Pfizer library of novel chemical entities in order to screen it for compounds that they develop into new treatments for the diseases. Vice president and chief scientific officer of antivirals research at Pfizer Global Research & Development Dr. Manos Perros said, "Despite considerable progress made in recent years, these three diseases continue to take a terrible human toll and represent a significant social burden for developing countries. We are expanding our commitment to the fight against tropical diseases by joining forces with DNDi by sharing our collection of chemical compounds and the knowledge and expertise associated with these chemical entities."

Contact Chip Brian

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html